课题基金 / 基金详情

I-Corps: Artificial Tissue Scaffolds and Cell Cultures Interlaced with Vasculature-like Micro-Channels

I-Corps: Artificial Tissue Scaffolds and Cell Cultures Interlaced with Vasculature-like Micro-Channels
I-Corps:人造组织支架和细胞培养物与类似脉管系统的微通道交错
批准号:
1953890
负责人:
Roman Voronov
金额:
$5.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-02-01 至 2022-01-31

项目摘要

项目成果

Roman Voronov的其他基金

相似基金

相关文献

中文摘要
翻译
I-Corps项目更广泛的影响/商业潜力是一个新的工程组织培养平台,将加速再生医学技术向临床市场的转化。根据美国卫生与公众服务部的数据,2018年,美国需要救命器官移植的11.5万人中,只有10%的人接受了移植。生产可行的人工组织的一个主要障碍是产品的可变性。所提出的技术克服了这一限制,使在人工组织培养过程中对任何位置的细胞行为进行非破坏性控制成为可能。此外,它允许对细胞行为进行无损分析,这将影响市场,因为与传统的(通常是牺牲的)分析相比,通过降低实验成本,培养物被用于生物分子的生产、毒性和药物测试等。最后,培养平台是自动化的,这一事实解决了采用此类技术的另一个主要后勤障碍,允许公司向医院员工提供计算机代码,而不必为每个新产品教他们定制培养协议。这个I-Corps项目将使人们更好地了解拟议的细胞培养技术如何为临床市场提供解决方案;同时也为组织工程行业的成员提供技术见解,并为他们现有的培养系统和实践提供重大改进的机会。提出的技术是一种组织工程支架与血管样微通道交错,有助于克服限制传统生物制造方法的主要瓶颈。此外,它还为涉及细胞培养的其他细分市场提供了多种好处。例如,该技术已被证明能够通过允许研究人员进行微型细胞活检和流出物的局部收集以进行非原位分析,从而实现新的发现;活细胞培养中的加和减细胞操作,组织图案和过度生长去除;建立动态药物梯度和定制给药方案;通过在大型培养物中深层滋养细胞并清除这些区域的代谢废物来克服尺寸限制。该奖项反映了美国国家科学基金会的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
英文摘要
The broader impact/commercial potential of this I-Corps project is a novel engineered tissue culturing platform that will accelerate the translation of regenerative medicine technologies to the clinical market. According to the U.S. Dept. of Health & Human Services, only 10% of the 115k people in the U.S needed a lifesaving organ transplant in 2018 received it. A major obstacle to producing viable artificial tissues is product variability. The proposed technology overcomes that limitation by enabling non-disruptive control over the cell behavior at any location within the living artificial tissues as they are being cultured. Additionally, it allows for nondestructive analysis of the cell behavior, which will impact the markets where the cultures are used for things like production of biological molecules, toxicity and pharmaceutical testing, etc., by lowering experiment costs relative to the conventional (typically sacrificial) analysis. Lastly, the fact that the culturing platform is automated solves another major logistical hurdle to the adoption of such technologies, by allowing companies to provide computer codes to hospital staff instead of having to teach them custom culturing protocols for each new product. This I-Corps project will allow for better understanding of how the proposed cell culturing technology can offer solutions to the clinical market; while also providing technological insight to members of the tissue engineering industry, and opportunities for significant improvements to their existing culturing systems and practices. The proposed technology is a tissue engineering scaffold interlaced with vascular-like microchannels, which help to overcome major bottlenecks limiting the conventional biomanufacturing approaches. Additionally, it offers multiple benefits to other market segments that involve cell culturing. For example, the technology has been demonstrated to enable new discoveries by allowing researchers to perform localized collections of mini cell biopsies and effluent for ex-situ analysis; additive and subtractive cell operations in living cell cultures, tissue patterning and overgrowth removal; establishing dynamic drug gradients and custom delivery protocols; overcoming size-limitations by nourishing cells deep within large cultures and removing metabolic waste from those regions.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Ranking migration cue contributions to guiding individual fibroblasts faced with a directional decision in simple microfluidic bifurcations
对迁移线索的贡献进行排名,以指导单个成纤维细胞在简单的微流体分叉中面临方向性决策
DOI: 10.1093/intbio/zyz018
发表时间: 2019
期刊: Integrative Biology
影响因子: 2.5
作者: [Pham, Quang Long, Tong, Anh, Rodrigues, Lydia N, Zhao, Yang, Surblyte, Migle, Ramos, Diomar, Brito, John, Rahematpura, Adwik, Voronov, Roman S]
通讯作者: Voronov, Roman S
DOI: 10.1021/acsbiomaterials.9b01969
发表时间: 2020-03-01
期刊: ACS BIOMATERIALS SCIENCE & ENGINEERING
影响因子: 5.8
作者: [Anh Tong, Quang Long Pham, Voronov, Roman]
通讯作者: Voronov, Roman
PFI-TT: Development of an Automated Cell Culturing Platform for Highly Efficient and Reliable Drug Testing in Physiologically Representative Disease Models
  • 批准号:
    2141029
  • 项目类别:
    Standard Grant
  • 资助金额:
    $25.0万
  • 财政年份:
    2022
  • 负责人:
    Roman Voronov
  • 依托单位:
海外基金